AEON AEON Biopharma, Inc.
Pharmaceutical Preparations · NYSE · SEC CIK 1837607 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-1,587,233.3%
TTM EPS YoY-222.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-416.6%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets83.1%
Debt / equity0.00x
Current ratio2.75x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.35x
Accruals ratio-269.9%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | — | — | — | — |
| R&D expense | $4.09M | $14.18M | $34.75M | — |
| SG&A expense | $12.21M | $13.64M | $13.68M | — |
| Operating income | -$12.80M | $72.98M | -$48.43M | -$1.94M |
| Pretax income | -$39.22M | $42.01M | -$52.56M | $8.20M |
| Income tax | $0 | $0 | $0 | — |
| Net income | -$39.22M | $42.01M | -$52.56M | $8.20M |
| EBITDA | -$12.72M | $73.08M | -$48.36M | — |
| EPS (basic) | -3.95 | 77.74 | -0.38 | — |
| EPS (diluted) | -3.95 | 72.93 | -0.38 | — |
| Weighted avg. shares (diluted) | 9.92M | 575,945 | 138.85M | — |
| Balance sheet | ||||
| Cash & equivalents | $3.01M | $13,000 | $9.75M | $5.13M |
| Current assets | $3.40M | $1.59M | $9.84M | $835,224 |
| PP&E, net | $162,000 | $235,000 | $431,000 | — |
| Total assets | $5.56M | $3.14M | $10.78M | $276.95M |
| Current liabilities | $6.90M | $14.15M | $82.57M | $834,585 |
| Total liabilities | $60.59M | $31.71M | $143.24M | $17.88M |
| Shareholders' equity | -$55.03M | -$28.57M | -$287.50M | -$16.93M |
| Shares outstanding | 12.11M | 555,511 | 138.83M | — |
| Cash flow statement | ||||
| Operating cash flow | -$17.31M | -$20.29M | -$35.58M | -$1.49M |
| Capital expenditure | $4,000 | — | $306,000 | — |
| Free cash flow | -$17.31M | — | -$35.89M | — |
| Investing cash flow | -$4,000 | — | -$306,000 | -$276.00M |
| Financing cash flow | $20.30M | $15.15M | $40.51M | $277.99M |
| Depreciation & amortization | $78,000 | $97,000 | $68,000 | — |
| Stock-based compensation | $5.32M | $6.25M | $5.89M | — |
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.